ClinicalTrials.gg
CompletedNCT06674941Updated Nov 5, 2024

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

A Phase 1 interventional study of Teprotumumab in Healthy Volunteers, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.
  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing teprotumumab in Graves Ophthalmopathy — 2 open to participants now, 3 under way, 1 of them phase 3. teprotumumab · Graves Ophthalmopathy.

Enrollment
8th of 12
44 · median 56
Started
2023
the only one that year
Phase 1
4 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
10 of 12
Amgen

Among the 12 studies testing teprotumumab in Graves Ophthalmopathy, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 4 in phase 1, and was the 9th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

2 of the 12 studies testing teprotumumab in Graves Ophthalmopathy are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teprotumumab

teprotumumab: first FDA approval 2020 (TEPEZZA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing teprotumumab in Graves Ophthalmopathy, or all of them as a file.
02

Study summary

The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and to assess the PK of teprotumumab delivered by syringe pump and by an injection device in non-Japanese participants.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Thyroid eye disease
  • Graves' ophthalmopathy
  • Graves' orbitopathy
  • Thyroid-associated ophthalmopathy
  • Immunology
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is a healthy male or female between the ages of 18 and 55 years, inclusive, at Screening.
  2. Participant has a between 18 and 30 kg/m\^2, inclusive, at Screening.
  3. Participant is medically healthy, with no medical history, physical examination, laboratory profiles, vital signs, or 12-lead results at Screening, as deemed by the Principal Investigator (PI) or designee.
  4. If female of (including those with an onset of menopause \< 2 years prior to Screening, non-therapy-induced amenorrhea for \< 12 months prior to Screening or not surgically sterile [absence of ovaries and/or uterus]) must have a negative serum pregnancy test at Screening and Check-in and negative urine pregnancy tests at all protocol-specified time points (ie, prior to the teprotumumab dose and throughout participation in the Follow-up Period); female participants of childbearing potential who are sexually active with a non-vasectomized male partner must agree to use 2 reliable forms of during the trial, 1 of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started at least 1 full cycle prior to Day 1 and continue for 180 days after receiving the dose of teprotumumab. Highly effective contraceptive methods (with a failure rate \< 1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, vasectomized partner, or sexual abstinence. Abstinence should only be used as a contraceptive method if it is in line with the participant usual and preferred lifestyle. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) is not an acceptable method of contraception.
  5. If female, participant must agree not to donate an egg/oocyte from Day 1 until 180 days after receiving the dose of teprotumumab.
  6. If male, participant must be surgically sterile for at least 6 months prior to dosing or, if sexually active with a female partner of childbearing potential, must agree to use a barrier contraceptive method from Screening through 180 days after receiving the dose of teprotumumab.
  7. If male, must agree not to donate sperm from Day 1 until 180 days after receiving the dose of teprotumumab.
  8. Participant has adequate venous access.
  9. Participant understands the trial procedures in the ICF and is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

    Additional Inclusion Criteria for Cohort 2:

  10. First generation Japanese healthy male or female participants must meet all of the following as confirmed by interview:

    1. Descendants of 4 ethnic Japanese grandparents who were born in Japan
    2. Both parents are ethnic Japanese who were born in Japan
    3. Hold a Japanese passport or identity papers
    4. Have lived outside Japan for less than 10 years at the time of screening and lifestyle including diet has not changed significantly since leaving Japan.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a history or presence of a medical or psychiatric condition or disease, in the opinion of the PI or designee.
  2. Participant has a history of any illness that, in the opinion of the PI or designee, might confound the results of the trial or pose an additional risk to the participant due to participation in the trial.
  3. Participant has a history or presence of alcoholism (defined as > 10 standard drinks per week, where 1 standard drink = 284 mL of full-strength [4.9% alc/vol] beer, 30 mL of 40% [alc/vol] spirit or a 100 mL glass of wine]) or drug abuse within the 6 months prior to Day 1 dosing.
  4. Participant has a history or presence of or idiosyncratic reaction to components of teprotumumab or prior hypersensitivity reactions to a monoclonal antibody or history.
  5. Participant has a history or presence of:

    1. thyroid eye disease
    2. diagnosis of diseases
    3. inflammatory bowel disease
  6. Participant has an or aspartate transaminase level > 1.5 times at Screening or Check-in.
  7. Participant has ≥ 6.5% and/or fasting glucose level (after at least an 8-hour fast) > 126 mg/dL at Screening.
  8. Participant has clinically significant abnormal measurements at Screening or prior to teprotumumab dosing, in the opinion of the PI, or has second- or third-degree atrioventricular block or any of the following:

    1. QRS > 120 msec
    2. ) > 450 msec (males) or > 470 msec (females)
    3. PR interval > 220 msec
  9. Participant has a medical condition associated with increased risk of bleeding, including history of hematological diseases such as acquired disorders and coagulation disorders, including drug-induced thrombocytopenia, idiopathic thrombocytopenia or von t medication.
  10. Participant has donated blood, has had significant blood loss, or has received a transfusion of any blood or blood products within 60 days prior to Day 1 or plasma donation within 7 days prior to Day 1.
  11. Participant has participated in another clinical trial within 30 days (or 5 half-lives of the trial drug, whichever is longer) prior to Day 1. The 30-day (or 5 half-lives) window will be derived from the date of last dosing in the previous trial to the date of Day 1 of the current trial.
  12. Participant has previous participation in a teprotumumab clinical trial or received teprotumumab or any anti-human insulin-like growth factor-1 receptor monoclonal antibody.
  13. Participant has any other condition that, in the opinion of the Investigator, would preclude inclusion in the trial.
  14. Participant has used any prescription (excluding hormonal ) or over-the-counter medications, including herbal or nutritional supplements, within 14 days before receiving the study drug. Over-the-counter use of acetaminophen (up to 2 g per day), topical eye drops, and topical creams are allowed. Use of other over-the-counter medications may be allowed at the discretion of Investigator with approval from the Medical Monitor.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Cohort 1: Teprotumumab

    Non-Japanese participants will receive SC injection of teprotumumab Dose A by a syringe pump.

    Drug: Teprotumumab

  • Experimental
    Cohort 2: Teprotumumab

    Japanese participants will receive SC injection of teprotumumab Dose A by a syringe pump.

    Drug: Teprotumumab

  • Experimental
    Cohort 3: Teprotumumab

    Non-Japanese participants will receive SC injection of teprotumumab Dose B by an injection device.

    Drug: Teprotumumab

Interventions

  • Administered as an SC injection.

    Also known as: Teprotumumab-trbw, TEPEZZA, HZN-001

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-time Curve (AUC) From Time 0 Extrapolated to Infinity (AUCinf) of Teprotumumab

    Time frame: Day 1 pre-dose to Day 57

  2. AUC From Time 0 to the Last Quantifiable Concentration (AUClast) of Teprotumumab

    Time frame: Day 1 pre-dose to Day 57

  3. Maximum Observed Serum Concentration (Cmax) of Teprotumumab

    Time frame: Day 1 pre-dose to Day 57

  4. Time to Cmax (Tmax) of Teprotumumab

    Time frame: Day 1 pre-dose to Day 57

Secondary outcomes

  1. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs, severe TEAEs, infusion-related reactions, injection-site reactions, and adverse device effects will be reported. Clinically significant changes in laboratory tests, vital signs and electrocardiograms (ECG) will be reported as adverse events.

    Time frame: Up to Day 57

  2. Number of Participants with Anti-drug Antibodies (ADA) to Teprotumumab

    Time frame: Day 1 pre-dose to Day 57

  3. Titer of Positive ADA to Teprotumumab

    Time frame: Day 1 pre-dose to Day 57

07

Study locations

1 site
  • PPD Development, LP
    Las Vegas, Nevada 89113-2237, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Nov 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 5, 2024
StartActual
Mar 24, 2023
Primary completionActual
Nov 14, 2023
CompletionActual
Nov 14, 2023
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06674941
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Mar 24, 2023
Primary completion
Nov 14, 2023
Completion
Nov 14, 2023
Last update
Nov 5, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion